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Introduction
Hepatitis D virus (HDV) is a circular single-stranded
RNA virus that requires the presence of hepatitis B
surface antigen (HBsAg) from hepatitis B virus (HBV)
for assembly and transmission.1,2 Approximately 350
million individuals are chronically infected with HBV
worldwide.3 Of these, nearly 8% are co-infected with
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Background: Hepatitis D virus (HDV) DNA vaccine can produce Th1 and cytotoxic T-cell immune responses but only
a low anti-HDV antibody titer is generated with a large hepatitis D antigen (L-HDAg) construct. In contrast, DNA vaccine
expressing small hepatitis D antigen (S-HDAg) can generate a high titer of anti-HDV antibodies. Whether the low
humoral immunity of L-HDAg DNA vaccine is due to inadequate dosage or can be ameliorated by other modes of
immunization needs further evaluation.
Methods: Plasmid (p25L) encoding L-HDAg and plasmid (pS/p25L) coexpressing hepatitis B surface antigen (HBsAg)
and L-HDAg were used in this study. We compared the humoral response generated in mice using different plasmid
DNA dosages and modes of immunization, including gene gun and in vivo electroporation (EP).
Results: Intramuscular injection with a high dose of plasmid DNA (10 mg/kg) produced strong antibodies to HBsAg
earlier than the usual dose did, but did not augment the anti-HDV response. Gene gun DNA immunization could
not provide a better humoral immune response to HDV. EP DNA immunization had a higher anti-HDV seroconversion
rate of 80%, but the anti-HDV antibody responses were generally weak (titer ) 400:1).
Conclusion: The low humoral immunogenicity of DNA vaccine with L-HDAg cannot be ameliorated by different dosage,
gene gun immunization, or in vivo EP intramuscular injection. DNA vaccine with a L-HDAg construct may not be a
candidate HDV vaccine to generate anti-HDV humoral immunity. [J Chin Med Assoc 2006;69(1):7–13]
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HDV.4 It is estimated that HDV infects 20 million
people globally.5 HDV superinfection is one of the
major causes of fulminant hepatitis in Taiwan.6
Superinfection with HDV often results in chronic
hepatitis, and many cases progress to cirrhosis.7–10
Furthermore, HDV superinfection also increases the
risk of hepatocellular carcinoma (HCC) and the
mortality in HBV-related cirrhotic patients.11
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Currently, there is still no effective treatment for
chronic hepatitis D (CHD). Interferon is a licensed
drug to treat CHD, but the relapse rate is high after
discontinuation.12 Lamivudine, a nucleotide analog,
can inhibit HBV replication but shows no response in
the treatment of CHD.13 It is necessary to develop an
alternative approach to prevent unfavorable outcomes
in patients with HDV infection. DNA vaccine can
induce a broad range of immune responses and is
considered to be a promising method to prevent and
treat persistent viral infections. The development of
HDV DNA vaccine has a potential use for HBV
carriers who are at risk of HDV superinfection or for
CHD patients to serve as a therapeutic agent.
HDV has 2 forms of viral proteins, large and small
hepatitis D antigens (HDAg). Large hepatitis D antigen
(L-HDAg) has an additional 19 amino acids at the
C-terminus of small hepatitis D antigen (S-HDAg)
due to an RNA editing event.14,15 Both antigens have
their distinct functions. L-HDAg is responsible for
HDV assembly and S-HDAg is responsible for viral
replication.2,16 Our previous study demonstrated that
HDV DNA vaccine produces Th1 immune response
to HDV, but L-HDAg-encoded DNA vaccine could
only produce low titers of anti-HDV antibody.17 In
contrast, DNA vaccine expressing S-HDAg can
generate stronger anti-HDV antibody titers.18 The
gene gun approach has been reported to increase
antibody responses.19 Another new mode of DNA
vaccine immunization, electroporation (EP), can
greatly increase the uptake of DNA into cells and is
capable of overcoming the cell barrier to enhance the
antibody responses.20,21 In addition, the optimal dosage
of DNA immunization is still uncertain. Therefore, it
is of interest to determine whether the low humoral
immunity of DNA vaccine with L-HDAg construct is
due to inadequate dosage or can be ameliorated by
other modes of immunization. Consequently, we
conducted this study to compare the humoral responses
generated in mice using different DNA dosages, gene
gun immunization, and in vivo EP intramuscular
injection.
Methods
Construction of expression vector
The L-HDAg gene was amplified by polymerase chain
reaction (PCR) with pairs of primers (bx25: 5'
GGCTCTAGAGTAAGAGTACTGAGG 3' and bS:
5' TCATGCATGCCGACCCGAAGAGGA 3') from
plasmid TWD2667 (AF104263), which contained
the HDV coding region (genotype I) in the PCR II
vector, and cloned into the Xba I/Sph I sites in
plasmid pCMV EBNA (Invitrogen, San Diego, CA,
USA) to produce plasmid p25L.17 A bicistronic plasmid,
pTCAE,17,22 was used to express HBV major S protein
(adw) and L-HDAg (genotype I) in the same construct
but under discrete CMV promoter control. The HBV
major S gene was amplified by PCR from plasmid
pEco63 (ATCC 31518; American Type Culture
Collection, Rockville, MD, USA) with pairs of primers
(5' ACCCTAGATCTAACATGGAGAACA 3' and 5'
GCCGAAGCTTACTAGTTACCCAGAGACA 3')
and cloned into the Bgl II/Hind III sites of pTCAE
to generate plasmid pTCAE/S. The L-HDAg gene
wa s  amp l i f i ed  b y  p a i r s  o f  p r ime r s  ( 5 '
TCTTGTCGACATGAGCCGTTCCGAG 3' and 5'
CGAGATCTTCACTGGGGTCGGCAACTC 3') and
cloned into the Sal I/Bam HI sites of pTCAE/S to
generate the bicistronic plasmid designated pS/p25L.
The expression of HDAg or HBsAg by plasmid p25L
or  pS/p25L ha s  been  demons t r a t ed  by
immunohistostaining in our previous work.17 Plasmid
pcDNA3 was used as a negative control. Plasmid DNA
was purified from transformed Escherichia coli DH5_
(Gibco BRL, Life Technologies, Gaithersburg, MD,
USA) using a QIAGEN Giga plasmid purification kit
(TAIGEN Bioscience Corporation, Taipei, Taiwan)
and stored as pellets at –70$C. DNA was reconstituted
in sterile saline at a concentration of 1 mg/mL for
experimental use.
Animals
Female BALB/c mice were obtained from the National
Laboratory Animal Breeding and Research Center
(Taipei, Taiwan). Mice were housed at the Laboratory
Animal Facility, Taipei Veterans General Hospital,
and were immunized at 6–8 weeks of age.
Immunization
Intramuscular immunization
For intramuscular DNA immunization, cardiotoxin
(Sigma, St Louis, MO, USA) was given to each
mouse 1 week before immunization.17,18 Groups of
mice were anesthetized and given intramuscular
injections, into the bilateral quadriceps, at a total
dose of 200 +g of plasmid DNA dissolved in 100 +L
of sterilized normal saline. Groups of 5 mice were
immunized as follows: group 1 with 200 +g of p25L;
group 2 with 100 +g of p25L plus 100 +g of
pcDNA3; group 3 with 200 +g of pS/25L; group 4
with 100 +g of pS/25L plus 100 +g of pcDNA3;
and group 5 with 200 +g of pcDNA3. Each mouse
was given booster doses 3 and 6 weeks after the first
immunization.
L-HDAg DNA vaccine
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Gene gun immunization
For gene gun DNA immunization, a hand-held,
helium-driven Helios gene delivery system (Bio-Rad,
Hercules, CA, USA) was used.23 Plasmid DNA was
precipitated onto gold particles with a 1.6-+m average
diameter, as specified by the manufacturer. The inner
surface of a Tefzel (Bio-Rad) tubing was coated with
the DNA-gold particle preparation with a tube loader
(Bio-Rad), and the tubing was cut into 0.5-inch
segments for delivery of 0.5 mg of gold and 1 +g of
plasmid DNA per shot. Groups of 5 mice were
immunized with the gene gun as follows: group 6
with p25L; group 7 with pcDNA3. Each animal
received a gene gun injection into the abdominal
epidermis 3 times at 3-week intervals with a helium
pressure setting of 500 lb/in2. Another group of mice
(group 8) was intramuscularly immunized with
100 +g of p25L to serve as a control. Group 8 mice
were given cardiotoxin pretreatment 1 week prior to
immunization and 2 booster doses 3 and 6 weeks
after the first immunization.
Electroporation
In vivo EP intramuscular injection was performed as
previously described with some modifications.24,25 Mice
were anesthetized with acepromazine maleate
(Fermenta Animal Health Co., Kansas City, MO,
USA). One hundred micrograms of plasmid DNA was
injected into the bilateral quadricep muscles.
Immediately after the injection, a pair of electrode
needles was inserted into the muscle to a depth of 5
mm to encompass the DNA injection sites, and electric
pulses were delivered using an electric pulse generator
(Electro Square Porator ECM 830; BTX, San Diego,
CA, USA). The shape of the pulse was a square wave.
The electrodes consisted of a pair of gold-plated
stainless steel needles 5 mm in length and 0.8 mm in
diameter, with a fixed distance of 5 mm between them.
Ten pulses of 900 V each were administered to each
injection site at a rate of 1 pulse/second, with each pulse
being 100 +s in duration. Groups of 5 mice were
immunized as follows: group 9 with 100 +g of p25L
and group 10 with 100 +g of pcDNA3. Each mouse
was given booster doses 3 and 6 weeks after the first EP
immunization. Another group of mice (group 11) was
intramuscularly immunized with 100 +g of p25L
without EP. This group of mice was given 2 booster
doses 3 and 6 weeks after the first immunization.
Serum sampling
Serum samples were collected by tail bleeding before
each immunization, and 9 and 12 weeks after the first
immunization.
Enzyme-linked immunosorbent assay (ELISA)
of anti-HBs and anti-HDV antibodies
The total anti-HBs antibodies (Ab) were quantitated
using the AUSAB-EIA kit (Abbott Laboratories, North
Chicago, IL, USA). Assays were performed as specified
by the manufacturer. The amount of anti-HBs antibody
was calculated from a standard curve generated by
using the anti-HBs positive control provided in the
AUSAB quantitation panel (Abbott Laboratories).
Serum samples from groups of mice were analyzed for
the presence of HDAg-specific antibodies according
to our previous reports.17,18 In brief, microtiter plates
were coated with 100 +L (1 +g/mL) of a fusion
protein containing maltose-binding protein (MBP)
and L-HDAg (MBP-DL2577), as reported previously.26
After blocking, 100 +L of serial dilutions of tested sera
in triplicate were added to each well. Bound proteins
were detected with horseradish peroxidase (HRP)-
conjugated goat anti-mouse immunoglobulin G (IgG)
(Sigma).  Color  was  generated by adding
0.1 M citric acid (pH 5) and phenyldiamine (Sigma).
The absorbance at 490 nm was measured on an ELISA
reader. The results were considered significant if the
optical density (OD) value of the tested sera was
higher than the mean OD value + 3 SD of the control
sera.
Statistical analysis
To compare the results between groups, the Wilcoxon
signed-rank test was used. To compare the results
among groups, a Kruskal-Wallis 1-way analysis of
variance (ANOVA) was used.27 A p value < 0.05 was
considered significant.
Results
Humoral responses to intramuscular
immunizations
Plasmid pS/p25L could co-express L-HDAg and
HBsAg. When anti-HBsAb was detected after DNA
immunization, it was confirmed to be successful.
Consequently, plasmid pS/p25L was adopted in this
study to serve as a control. As shown in Figure 1, mice
immunized with pS/p25L showed a strong anti-HBs
response and a seroconversion rate of 100%. Clinically,
a protective immunity against HBV infection is at a
level of 10 mIU/mL of anti-HBs antibody based on
World Health Organization reference values. The
maximal anti-HBs antibody response after DNA
immunization was achieved in week 9 (> 300 mIU/
mL). Mice immunized with 200 +g of pS/25L could
reach a high anti-HBs response beginning at week 6,
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about 3 weeks earlier than those immunized with 100 +g
of pS/25L. However, the anti-HBs responses of both
groups of mice were nearly identical in weeks 9 and
12. No statistical difference was noted between these
2 groups (p > 0.05).
The anti-HDV humoral immune response to
various plasmids at different dosages was assessed
(Figure 2) and was shown to be weak after intramuscular
immunization with L-HDAg DNA vaccine. Even
though the anti-HBs titers were high in mice
immunized with pS/p25L, titers for anti-HDV
antibodies were low. The anti-HDV seroconversion
rate was 60% in group 1 compared to group 4 mice. It
is worth noting that doubling the dosage of plasmid
DNA could not augment the anti-HDV response.
Humoral responses to gene gun immunization
Gene gun immunization is a route of intra-epidermal
DNA transfection. As shown in Figure 3, gene gun
DNA immunization with L-HDAg plasmid could not
provide a better humoral immune response to HDV.
The anti-HDV titers were even lower than in the
intramuscular route, but without statistical significance.
The anti-HDV seroconversion rate was 60% for both
routes of immunization.
Humoral responses to EP DNA immunization
The anti-HDV antibody titers in mice immunized
with p25L by EP DNA immunization were similar to
Figure 1. Kinetics of anti-HBs antibodies in mice immunized with
200 +g of plasmid pS/p25L () or 100 +g of pS/p25L plus 100
+g of pcDNA3 (). All mice were given an intramuscular injection
of 200 +g of plasmid DNA at 0, 3 and 6 weeks (). Sera were
obtained at different time points and assayed for the presence of
anti-HBs. Concentrations of anti-HBs antibodies were quantitated
with a commercial kit, and values were determined relative to the
standard reference preparation. Mean titers are expressed in
milli-international units per milliliter (mIU/mL). The threshold for
seroconversion was defined as * 10 mIU/mL. The data are
presented as mean ( SD for 5 animals per time point.
Figure 2. Kinetics of anti-HDV antibodies in mice immunized
with 200 +g of plasmid pS/p25L (), 100 +g of pS/p25L plus
100 +g of pcDNA3 (), 200 +g of p25L (), 100 +g of p25L plus
100 +g of pcDNA3 (), or 200 +g of pcDNA3 (). Immunization
at 0, 3 and 6 weeks (). After intramuscular injection, sera
were assayed for the presence of anti-HDV. Titers of anti-HDV
antibodies were assayed by ELISA and determined by a serial
dilution of the sera. The results were defined as significant if
the OD 490 value was greater than the mean OD + 3 SD of the
control sera. The data were presented as mean (  SD for 5
animals per time point.
those in mice immunized by intramuscular injection
(Figure 4). The titers also peaked at 9 weeks. Generally,
the anti-HDV titers were also low by EP immunization
(titer < 400:1). However, EP DNA immunization had
an anti-HDV seroconversion rate of 80%, which seemed
better than intramuscular injection alone (60%).
Discussion
HDV DNA vaccine with L-HDAg can produce Th1
immune response to HDV but the anti-HDV titer is
weak by this mode of immunization.17 In this study,
we doubled the plasmid DNA to 200 +g per injection
for each mouse. This dosage is equivalent to 10 mg/kg
for a mouse that weighs 20 g. At this dosage, mice
immunized with pS/p25L could rapidly reach high
anti-HBs antibody titers in 6 weeks. However, the
anti-HDV response was still weak regardless of dosage
change. All mice immunized with pS/p25L had
seroconversion to anti-HBs-positive, which confirmed
that the immunization technique was successful.
According to our previous reports, the anti-HDV
seroconversion rate was around 60% for mice
immunized with L-HDAg DNA vaccine.17,18
Comparable with these results, the anti-HDV
seroconversion rate was 60% by intramuscular
immunization, and was unaffected by the dosage
increment.
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Gene gun immunization can propel gold beads
coated with DNA into the epidermis. In a clinical trial
of HBV DNA vaccine with a gene gun, all vaccinees
immunized with plasmid encoding HBsAg
seroconverted. Most importantly, some of them failed
to respond to the licensed recombinant protein
vaccine.28,29 Although gene gun DNA immunization
has been proven to generate an antibody response, the
anti-HDV titers in mice after gene gun immunization
with L-HDAg DNA vaccine are still low. The anti-
HDV seroconversion rate was nearly the same in mice
immunized by intramuscular injection or gene gun.
The humoral immunogenicity of DNA vaccine with
L-HDAg could not be improved by this mode of
immunization.
In vivo EP intramuscular injection is a new delivery
device that increases the uptake of DNA into cells and
expression of encoded protein.20,21 This approach makes
holes in cells by simply delivering electric current in
vivo and permits the injected DNA to enter the cells
more efficiently. In this study, EP DNA immunization
improved the anti-HDV seroconversion rate to 80%.
Thus, EP substantially increased the DNA uptake after
injection of HDV DNA vaccine. However, even under
a more optimal condition of DNA transfection, the
anti-HDV antibody titer was still low. Consequently,
this low humoral immunogenicity of DNA vaccine
with L-HDAg is not related to modes of immunization
or the efficiency of DNA transfection. Consistent with
our recent finding, the immunogenicity of DNA
vaccines with large or small HDAg is different.18 The
low humoral immunogenicity of DNA vaccine with
L-HDAg arises from the masking effect of the
isoprenylated motif. This motif of L-HDAg can mask
the B-cell epitope of HDAg at the location of amino
acids 170–195 but does not interfere with the cellular
immunity following DNA-based immunization.18 This
may explain why the DNA dosage and modes of
immunization are not related to the antibody response
of DNA vaccine with L-HDAg.
HDAg is an intracellular antigen. The weak humoral
immunogenicity of L-HDAg DNA vaccine may be
due to its intracellular location in nature. However, a
recent study using expression vector to secrete HDAg
showed no improvement in anti-HDV response.30 In
this study, we adopted BALB/c mice for study as this
inbred mouse strain can produce an anti-HDV titer
using S-HDAg DNA vaccine.18 Consequently, the
possibility that HDAg response might be under the
control of a specific mouse immune response gene
should be ignored.
HDV DNA vaccine has been proven to produce Th1
immune response, HDV-specific interferon-a secreting
CD8 T cells, and cytotoxic T-cell response.17,18,30
Currently, there is no doubt that HDV DNA vaccine
can generate cellular immunity. In a woodchuck
model, HDV DNA vaccine seemed to be able to
modulate the disease course of HDV superinfection
but the protective ability was not sufficient.31 In that
experiment, no anti-HDV antibody was induced by
HDV DNA vaccine before HDV challenge. Generally,
both humoral and cellular immunity are necessary for
a protective vaccine. Although the neutralizing ability
of the anti-HDV antibodies is undetermined, a stronger
anti-HDV humoral immune response in cooperation
with cellular immune responses might be important
Figure 4. Kinetics of anti-HDV antibodies in mice immunized with
100 +g of plasmid p25L by EP (), 100 +g of p25L by the
intramuscular route (), or 100 +g of pcDNA3 by EP ().
Immunization at 0, 3 and 6 weeks (). After injection, sera were
assayed for the presence of anti-HDV. The data are presented as
mean ( SD for 5 animals per time point.
Figure 3. Kinetics of anti-HDV antibodies in mice immunized with
1 +g of plasmid p25L by gene gun (	), 100 +g of p25L by the
intramuscular route (), or 1 +g of pcDNA3 by gene gun ().
Immunization at 0, 3 and 6 weeks (). After injection, sera were
assayed for the presence of anti-HDV. The data are presented as
mean ( SD for 5 animals per time point.
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for a candidate HDV vaccine. In a human study, it was
discovered that HDV variants with amino acid changes
in B-cell epitopes usually emerged after a severe hepatitis
attack in CDH patients.32 This finding implies that the
anti-HDV antibodies might have immune selection
effects, which can deteriorate as a result of the low
humoral response generated by the L-HDAg construct
DNA vaccine.
In conclusion, the low humoral immunogenicity
of DNA vaccine with L-HDAg construct cannot be
improved by different dosages, gene gun immunization,
or in vivo EP intramuscular injection. DNA vaccine
with L-HDAg construct may not be a candidate HDV
vaccine.
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